Kyowa Kirin was represented by Goldman Sachs Japan Co., Ltd. as financial advisor and Morrison & Foerster LLP. as legal advisor. Orchard Therapeutics was represented by...
You must be a Standard 1 Year member to access this content.
Goodwin Procter represented Intellia Therapeutics, while Latham & Watkins LLP represented the underwriter in the offering. Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused...
You must be a Standard 1 Year member to access this content.
VISCHER AG advised Versantis with Mark Fitzpatrick as CEO, Vincent Forster as CSO and Meriam Kabbaj as COO. Goodwin advised the sellers. Linklaters and Niederer Kraft...
You must be a Standard 1 Year member to access this content.
Goodwin advised Precision Healing on the deal. Precision Healing announced its acquisition by Sanara MedTech. Precision Healing develops, markets, and distributes advanced wound care and diagnostic products...
You must be a Standard 1 Year member to access this content.
Goodwin advised Gandeeva on the deal. Gandeeva announced its Series A funding led by Lux Capital and Leaps by Bayer, with participation from Obvious Ventures, Amgen Ventures,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Wellframe on the deal. Wellframe Inc. announced its definitive agreement to be acquired by HealthEdge Software. Wellframe strategically partners with health plans nationwide to...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Garuda Therapeutics on the deal. Garuda Therapeutics announced its launch and $72 million Series A financing led by Aisling Capital, Northpond Ventures, and OrbiMed,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Neuroelectrics on the deal. Neuroelectrics announced its $17.5 million Series A financing led by Morningside Ventures. Neuroelectrics is developing a therapeutic platform that...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Chiasma, Inc. on the deal. Chiasma, Inc. (Nasdaq: CHMA) announced its definitive agreement to be acquired by Amryt Pharma plc (Nasdaq: AMYT, AIM:...
You must be a Standard 1 Year member to access this content.
